Trelegy Ellipta · DIN 02474522 · 100 mcg & 62.5 mcg & 25 mcg · dry-powder inhaler, 30 doses
Limited Use, Reason for Use code 567 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 567 required
Write on scriptReason for Use code 567 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 567
Reason for Use code 567
For the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients who require a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA).
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Trelegy Ellipta · DIN 02474522
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2019-09-30
Health Canada: Marketed since 2018-05-30 · brand TRELEGY ELLIPTA · ATC R03AL08 VILANTEROL, UMECLIDINIUM BROMIDE AND FLUTICASONE FUROATE, R03AL08 VILANTEROL, UMECLIDINIUM BROMIDE AND FLUTICASONE FUROATE, R03AL08 VILANTEROL, UMECLIDINIUM BROMIDE AND FLUTICASONE FUROATE · form Powder · route Inhalation · ingredients UMECLIDINIUM (UMECLIDINIUM BROMIDE) 62.5 MCG/ACT, VILANTEROL (VILANTEROL TRIFENATATE) 25 MCG/ACT, FLUTICASONE FUROATE 100 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Trelegy Ellipta: Formulary list price $137.67 per unit (the source does not state the unit; exact figure $137.6700). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02474522)
Source record
DIN 02474522: Trelegy Ellipta
Raw flags: sec12=Y, sec3=Y
Item: 121200114; group id 223; item number 0401; lccId 00321; manufacturer id GSK
Source form: Pd Inh-30 Dose Pk; strength: 100mcg & 62.5mcg & 25mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $137.6700; ministry $137.6700
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474522
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96469
Therapeutic Notes (formulary)
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Shortage status: resolved shortage (ended January 3, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02474522
Shortage record checked October 6, 2026